Skip to Content
Merck
CN

SML4152

Ipragliflozin

≥98% (HPLC)

Synonym(s):

(1S)-1,5-Anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol, (2S,3R,4R,5S,6R)-2-(3-(Benzo[b]thien-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, ASP-1941

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C21H21FO5S
CAS Number:
Molecular Weight:
404.45
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

O[C@H]1[C@@H](O[C@H](CO)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=CC=CC=C4S3)=C(F)C=C2

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

Biochem/physiol Actions

Ipragliflozin is a potent and highly selective sodium-glucose cotransporter-2 (SGLT2) inhibitor, demonstrating excellent oral bioavailability with an IC50 of 1,876 nM for SGLT1and 7.38 nM for hSGLT2. Ipragliflozin features dose-dependent pharmacokinetics, effectively induces glucosuria, and has been shown to decrease blood glucose levels, reduce blood pressure, lower body weight, and diminish both hypoglycaemic risk and abdominal symptoms in diabetic patients. Additionally, Ipragliflozin increases insulin levels in the pancreas and prevents the loss of insulin-positive cells in islets of db/db mice. ASP-1941 also maintains a favourable safety profile as monotherapy and is compatible with other hypoglycaemic agents, such as sulphonyl urea, metformin, pioglitazone, and dipeptidyl peptidase-4 (DPP4) inhibitors. Ipragliflozin has been considered as an anti-obesity and anti-diabetic agent.

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tsuyoshi Ohkura
World journal of diabetes, 6(1), 136-144 (2015-02-17)
Sodium-glucose cotransporter 2 (SGLT2) inhibition induces glucosuria and decreases blood glucose levels in diabetic patients and lowers hypoglycemic risk. SGLT1 is expressed in the kidney and intestine; SGLT1 inhibition causes abdominal symptoms such as diarrhea and reduces incretin secretion. Therefore

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service